US Stock Insider Trading | Rhythm disclosed one insider transaction on March 3

K-LinePoet · 2026-03-22T16:06:03+00:00

Rhythm (RYTM) disclosed an insider transaction on March 3, 2026, stating that executive German Christopher Paul sold 342 shares on March 1. Recently, Smith Hunter C also carried out multiple buy and sell transactions, with large trades indicating active market activity. Rhythm Pharmaceuticals focuses on the treatment of rare neuroendocrine diseases, with its main asset being IMCIVREE.

K-LinePoet

2026-03-22 16:06:03

Abstract generation in progress

On March 3, 2026, Rhythm (RYTM) disclosed a company insider trading activity. Executive German Christopher Paul sold 342 shares on March 1, 2026.

[Recent Insider Trading]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 3, 2026	Executive	German Christopher Paul	March 1, 2026	Sell	342	94.94	$32,500
March 2, 2026	Executive	Smith Hunter C	March 2, 2026	Buy	6,099	6.80	$41,500
February 19, 2026	Executive	Smith Hunter C	February 19, 2026	Sell	585	103.28	$60,400
February 19, 2026	Executive	Smith Hunter C	February 19, 2026	Sell	1,692	100.92	$170,800
February 19, 2026	Executive	Smith Hunter C	February 19, 2026	Sell	800	102.10	$81,700
February 19, 2026	Executive	Smith Hunter C	February 17, 2026	Sell	1,069	103.00	$110,100
February 19, 2026	Executive	Smith Hunter C	February 19, 2026	Sell	1,308	100.27	$131,200
February 19, 2026	Executive	Smith Hunter C	February 17, 2026	Sell	1,200	99.42	$119,300
February 19, 2026	Executive	Smith Hunter C	February 17, 2026	Sell	200	100.52	$20,100
February 19, 2026	Executive	Smith Hunter C	February 17, 2026	Sell	900	101.70	$91,500

[Company Profile]

Rhythm Pharmaceuticals, Inc. is a Delaware-based company founded in February 2013. It is a global, commercial-stage biopharmaceutical company dedicated to changing the lives of patients and their families affected by rare neuroendocrine diseases. The company focuses on advancing melanocortin-4 receptor (MC4R) agonists, including their flagship asset IMCIVREE, as targeted therapies designed to treat hyperphagia and severe obesity caused by rare MC4R pathway disorders.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.